The present application provides several crystalline forms of gemcitabine base and methods of making the same.

The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual...

The present invention provides, in part, compositions including an anti-IGF1R antibody or antigen-binding fragment thereof and any one or more of cisplatin, pemetrexed, gemcitabine and/or irinotecan

Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention wherein the definitions for the groups of a b c d E Z and V are described in the specification. By modifying the N4 group the solubility the bioavailability and the organ specificity of the prodrugs are improved. Therefore the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decr...

The application describes methods for predicting overall survival in subjects with breast cancer. The application also describes for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including gemcitabine. The application further describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including gemcitabine and administering the the...